JP2011507514A - Ｇタンパク質を発現する安定な細胞系を用いた、繁殖欠損水疱性口内炎ウイルスベクターをパッケージングする方法 - Google Patents
Ｇタンパク質を発現する安定な細胞系を用いた、繁殖欠損水疱性口内炎ウイルスベクターをパッケージングする方法 Download PDFInfo
- Publication number
- JP2011507514A JP2011507514A JP2010539474A JP2010539474A JP2011507514A JP 2011507514 A JP2011507514 A JP 2011507514A JP 2010539474 A JP2010539474 A JP 2010539474A JP 2010539474 A JP2010539474 A JP 2010539474A JP 2011507514 A JP2011507514 A JP 2011507514A
- Authority
- JP
- Japan
- Prior art keywords
- vsv
- protein
- cell
- seq
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711975 Vesicular stomatitis virus Species 0.000 title claims description 411
- 238000000034 method Methods 0.000 title claims description 187
- 108091006027 G proteins Proteins 0.000 title claims description 170
- 108091000058 GTP-Binding Proteins 0.000 title claims description 170
- 102000030782 GTP binding Human genes 0.000 title claims description 168
- 230000002950 deficient Effects 0.000 title claims description 32
- 238000004806 packaging method and process Methods 0.000 title claims description 26
- 239000013598 vector Substances 0.000 title description 107
- 210000004027 cell Anatomy 0.000 claims description 334
- 230000002238 attenuated effect Effects 0.000 claims description 139
- 241000700605 Viruses Species 0.000 claims description 122
- 108090000623 proteins and genes Proteins 0.000 claims description 117
- 230000014509 gene expression Effects 0.000 claims description 93
- 230000035939 shock Effects 0.000 claims description 81
- 101150082239 G gene Proteins 0.000 claims description 78
- 230000003612 virological effect Effects 0.000 claims description 72
- 239000000427 antigen Substances 0.000 claims description 68
- 108091007433 antigens Proteins 0.000 claims description 68
- 102000036639 antigens Human genes 0.000 claims description 68
- 239000013612 plasmid Substances 0.000 claims description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 230000001939 inductive effect Effects 0.000 claims description 54
- 108020004414 DNA Proteins 0.000 claims description 52
- 239000002299 complementary DNA Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 42
- 210000003501 vero cell Anatomy 0.000 claims description 38
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 33
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 32
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 30
- 239000013604 expression vector Substances 0.000 claims description 29
- 238000004520 electroporation Methods 0.000 claims description 28
- 108091033319 polynucleotide Proteins 0.000 claims description 26
- 102000040430 polynucleotide Human genes 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 26
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 26
- 230000002163 immunogen Effects 0.000 claims description 22
- 238000001890 transfection Methods 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 101710085938 Matrix protein Proteins 0.000 claims description 18
- 101710127721 Membrane protein Proteins 0.000 claims description 18
- 230000006698 induction Effects 0.000 claims description 18
- 101710141454 Nucleoprotein Proteins 0.000 claims description 17
- 210000005220 cytoplasmic tail Anatomy 0.000 claims description 16
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 16
- 230000035897 transcription Effects 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 238000004113 cell culture Methods 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 14
- 230000000120 cytopathologic effect Effects 0.000 claims description 13
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 12
- 101710181008 P protein Proteins 0.000 claims description 12
- 101710177166 Phosphoprotein Proteins 0.000 claims description 12
- 238000009395 breeding Methods 0.000 claims description 12
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 11
- 230000001488 breeding effect Effects 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 230000001419 dependent effect Effects 0.000 claims description 10
- 241000712079 Measles morbillivirus Species 0.000 claims description 9
- 230000014616 translation Effects 0.000 claims description 8
- 108010009460 RNA Polymerase II Proteins 0.000 claims description 7
- 102000009572 RNA Polymerase II Human genes 0.000 claims description 7
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 7
- 244000045947 parasite Species 0.000 claims description 7
- 244000052769 pathogen Species 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 241000701022 Cytomegalovirus Species 0.000 claims description 6
- 230000007547 defect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 206010064571 Gene mutation Diseases 0.000 claims description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 241000711386 Mumps virus Species 0.000 claims description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 4
- 241000711798 Rabies lyssavirus Species 0.000 claims description 4
- 238000001243 protein synthesis Methods 0.000 claims description 4
- 230000008093 supporting effect Effects 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 241000342334 Human metapneumovirus Species 0.000 claims description 3
- 241000701806 Human papillomavirus Species 0.000 claims description 3
- 241000713112 Orthobunyavirus Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 244000000010 microbial pathogen Species 0.000 claims description 3
- 230000025308 nuclear transport Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 description 39
- 108091026890 Coding region Proteins 0.000 description 38
- 239000002245 particle Substances 0.000 description 30
- 208000015181 infectious disease Diseases 0.000 description 29
- 238000005457 optimization Methods 0.000 description 24
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 22
- 230000035772 mutation Effects 0.000 description 20
- 230000033458 reproduction Effects 0.000 description 19
- 238000011084 recovery Methods 0.000 description 18
- 108090000288 Glycoproteins Proteins 0.000 description 17
- 230000010076 replication Effects 0.000 description 17
- 230000010474 transient expression Effects 0.000 description 17
- 102000003886 Glycoproteins Human genes 0.000 description 16
- 230000002458 infectious effect Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 101710145752 Serine recombinase gin Proteins 0.000 description 14
- 238000003501 co-culture Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 230000005847 immunogenicity Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 101100243399 Caenorhabditis elegans pept-2 gene Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 239000002356 single layer Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 102000053642 Catalytic RNA Human genes 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 8
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 239000013600 plasmid vector Substances 0.000 description 8
- 108091092562 ribozyme Proteins 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 108010067390 Viral Proteins Proteins 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241001493065 dsRNA viruses Species 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000000644 propagated effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101710154606 Hemagglutinin Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 5
- 101710176177 Protein A56 Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000002635 electroconvulsive therapy Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000000185 hemagglutinin Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 241000223960 Plasmodium falciparum Species 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 244000052637 human pathogen Species 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 101150034814 F gene Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 108060003393 Granulin Proteins 0.000 description 3
- 108010089430 Phosphoproteins Proteins 0.000 description 3
- 102000007982 Phosphoproteins Human genes 0.000 description 3
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 241000711931 Rhabdoviridae Species 0.000 description 3
- 241000220317 Rosa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 3
- 101710162629 Trypsin inhibitor Proteins 0.000 description 3
- 229940122618 Trypsin inhibitor Drugs 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 3
- 230000034303 cell budding Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000003169 complementation method Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003157 protein complementation Methods 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- 102000000039 Heat Shock Transcription Factor Human genes 0.000 description 2
- 108050008339 Heat Shock Transcription Factor Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 2
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 2
- 102100034574 P protein Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- -1 cationic lipid Chemical class 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229940038523 live rotavirus vaccine Drugs 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000030147 nuclear export Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000711443 Bovine coronavirus Species 0.000 description 1
- 108010059574 C5a peptidase Proteins 0.000 description 1
- 101100392472 Caenorhabditis elegans hse-5 gene Proteins 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 101900205472 Newcastle disease virus Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 241000224028 Plasmodium cynomolgi Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 241000702665 Porcine rotavirus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101150015069 RNAP gene Proteins 0.000 description 1
- 229940124679 RSV vaccine Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010015329 Respiratory syncytial virus G glycoprotein Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940124878 RotaTeq Drugs 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 241001415395 Spea Species 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108090000794 Streptopain Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 108700041558 Vesicular stomatitis virus M Proteins 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000012777 commercial manufacturing Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 101150034374 gin gene Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 108010015936 pseudorabies virus glycoprotein gH Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000009614 wildtype growth Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20251—Methods of production or purification of viral material
- C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1535307P | 2007-12-20 | 2007-12-20 | |
| PCT/US2008/013817 WO2009085172A1 (en) | 2007-12-20 | 2008-12-18 | Methods for packaging propagation-defective vesicular stomatitis virus vectors using a stable cell line that expresses g protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507514A true JP2011507514A (ja) | 2011-03-10 |
| JP2011507514A5 JP2011507514A5 (enExample) | 2012-02-09 |
Family
ID=40418917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539474A Pending JP2011507514A (ja) | 2007-12-20 | 2008-12-18 | Ｇタンパク質を発現する安定な細胞系を用いた、繁殖欠損水疱性口内炎ウイルスベクターをパッケージングする方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090162321A1 (enExample) |
| EP (1) | EP2225264A1 (enExample) |
| JP (1) | JP2011507514A (enExample) |
| AR (1) | AR069885A1 (enExample) |
| AU (1) | AU2008343919B2 (enExample) |
| CA (1) | CA2710166A1 (enExample) |
| CL (1) | CL2008003821A1 (enExample) |
| WO (1) | WO2009085172A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020534284A (ja) * | 2017-09-15 | 2020-11-26 | オハイオ ステート イノベーション ファウンデーション | ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9248178B2 (en) | 2009-06-08 | 2016-02-02 | Chil-Yong Kang | Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens |
| US9610346B2 (en) | 2012-03-23 | 2017-04-04 | International Aids Vaccine Initiative | Recombinant viral vectors |
| WO2019070704A1 (en) * | 2017-10-02 | 2019-04-11 | Georgia Tech Research Corporation | METHODS AND COMPOSITIONS FOR ENGINEERING SYNTHESIS BIOLOGICAL SWITCHES FOR REMOTE CONTROL OF BIOLOGICAL ACTIVITY |
| CN109750006A (zh) * | 2019-01-14 | 2019-05-14 | 青岛农业大学 | 一种犬瘟热病毒复制缺陷毒株及其构建方法 |
| CN112430582B (zh) * | 2020-12-04 | 2022-05-03 | 北京艺妙神州医药科技有限公司 | 一种慢病毒稳定包装细胞系及其制备方法 |
| CN115725657B (zh) * | 2022-09-16 | 2024-06-04 | 中国科学院广州生物医药与健康研究院 | 一种节段化的水泡性口炎病毒载体及其制备方法和应用 |
| CN117051040B (zh) * | 2023-08-15 | 2024-10-01 | 北京百普赛斯生物科技股份有限公司 | Vsv△g复制缺陷型病毒制备及应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001038488A2 (en) * | 1999-11-23 | 2001-05-31 | Mayo Foundation For Medical Education And Research | Gene expression by positive feedback activation of a cell type-specific promoter |
| WO2004113517A2 (en) * | 2003-06-09 | 2004-12-29 | Wyeth | IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US6596529B1 (en) * | 1997-05-02 | 2003-07-22 | Uab Research Foundation | Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof |
| US6136585A (en) * | 1997-05-02 | 2000-10-24 | Uab Research Foundation | Attenuation of negative stranded RNA viruses by rearrangement of genes and uses thereof |
| US8008268B2 (en) * | 2006-07-25 | 2011-08-30 | Merial Limited | Vaccines against vesicular stomatitis |
-
2008
- 2008-12-16 US US12/335,778 patent/US20090162321A1/en not_active Abandoned
- 2008-12-18 EP EP08867848A patent/EP2225264A1/en not_active Withdrawn
- 2008-12-18 CA CA2710166A patent/CA2710166A1/en not_active Abandoned
- 2008-12-18 AU AU2008343919A patent/AU2008343919B2/en not_active Ceased
- 2008-12-18 JP JP2010539474A patent/JP2011507514A/ja active Pending
- 2008-12-18 WO PCT/US2008/013817 patent/WO2009085172A1/en not_active Ceased
- 2008-12-19 AR ARP080105638A patent/AR069885A1/es unknown
- 2008-12-19 CL CL2008003821A patent/CL2008003821A1/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001038488A2 (en) * | 1999-11-23 | 2001-05-31 | Mayo Foundation For Medical Education And Research | Gene expression by positive feedback activation of a cell type-specific promoter |
| WO2004113517A2 (en) * | 2003-06-09 | 2004-12-29 | Wyeth | IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA |
Non-Patent Citations (3)
| Title |
|---|
| JPN5010015937; ＲＯＢＥＲＴＳ Ａ: 'ＡＴＴＥＮＵＡＴＥＤ ＶＥＳＩＣＵＬＡＲ ＳＴＯＭＡＴＩＴＩＳ ＶＩＲＵＳＥＳ ＡＳ ＶＡＣＣＩＮＥ ＶＥＣＴＯＲＳ' ＪＯＵＲＮＡＬ ＯＦ ＶＩＲＯＬＯＧＹ Ｖ７３ Ｎ５, 19990501, Ｐ３７２３-３７３２, ＴＨＥ ＡＭＥＲＩＣＡＮ ＳＯＣＩＥＴＹ ＦＯＲ ＭＩＣＲＯＢＩＯＬＯＧＹ * |
| JPN5010015938; ＫＡＨＮ Ｊ Ｓ: 'ＲＥＰＬＩＣＡＴＩＯＮ-ＣＯＭＰＥＴＥＮＴ ＯＲ ＡＴＴＥＮＵＡＴＥＤ， ＮＯＮＰＲＯＰＡＧＡＴＩＮＧ ＶＥＳＩＣＵＬＡＲ ＳＴＯＭＡＴＩＴＩＳ ＶＩＲＵＳＥＳ 以下備考' ＪＯＵＲＮＡＬ ＯＦ ＶＩＲＯＬＯＧＹ Ｖ７５ Ｎ２２, 20011101, Ｐ１１０７９-１１０８７, ＴＨＥ ＡＭＥＲＩＣＡＮ ＳＯＣＩＥＴＹ ＦＯＲ ＭＩＣＲＯＢＩＯＬＯＧＹ * |
| JPN5010015939; ＴＥＲＮＥＴＴＥ Ｎ: 'ＥＸＰＲＥＳＳＩＯＮ ＯＦ ＲＮＡ ＶＩＲＵＳ ＰＲＯＴＥＩＮＳ ＢＹ ＲＮＡ ＰＯＬＹＭＥＲＡＳＥ ＩＩ ＤＥＰＥＮＤＥＮＴ ＥＸＰＲＥＳＳＩＯＮ ＰＬＡＳＭＩＤＳ ＩＳ 以下備考' ＶＩＲＯＬＯＧＹ ＪＯＵＲＮＡＬ Ｖ４ Ｎ１, 20070605, ＢＩＯＭＥＤ ＣＥＮＴＲＡＬ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020534284A (ja) * | 2017-09-15 | 2020-11-26 | オハイオ ステート イノベーション ファウンデーション | ワクチン、並びに、呼吸器合胞体ウイルス（ｒｓｖ）感染症を予防するためのワクチンの作製方法及び使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008343919A1 (en) | 2009-07-09 |
| CL2008003821A1 (es) | 2009-04-03 |
| WO2009085172A1 (en) | 2009-07-09 |
| US20090162321A1 (en) | 2009-06-25 |
| EP2225264A1 (en) | 2010-09-08 |
| AR069885A1 (es) | 2010-02-24 |
| AU2008343919B2 (en) | 2013-01-17 |
| CA2710166A1 (en) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0871482B1 (en) | Recombinant vesiculoviruses and their uses | |
| JP5779226B2 (ja) | 水疱性口内炎ウイルスの相乗的弱毒化、そのベクター及びその免疫原性組成物 | |
| KR101020532B1 (ko) | ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의 회수를 위한 개선된 방법 | |
| CN104271594B (zh) | 用于初免‑加强疫苗的水疱性口炎病毒 | |
| JP2011507514A (ja) | Ｇタンパク質を発現する安定な細胞系を用いた、繁殖欠損水疱性口内炎ウイルスベクターをパッケージングする方法 | |
| US11896658B2 (en) | RSV vaccines and methods of production and use thereof | |
| CN105555958A (zh) | 水疱性口炎病毒的改性基质蛋白 | |
| JP2011507515A (ja) | 繁殖欠損水疱性口内炎ウイルスベクターをパッケージングする方法 | |
| AU2018392826B2 (en) | Lassa vaccine | |
| Von Messling et al. | Toward novel vaccines and therapies based on negative-strand RNA viruses | |
| EP3820884B1 (en) | Method for rescuing and producing a virus in avian cells | |
| CN101087886B (zh) | 疱疹性口炎病毒、其载体和其免疫原性组合物的协同减毒 | |
| JP2002513575A (ja) | 弱毒インフルエンザウイルス | |
| CN1416471A (zh) | 重组弹状病毒作为免疫缺陷病毒的活病毒疫苗 | |
| OA19870A (en) | Lassa vaccine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111212 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20121119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131022 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140421 |